Why BGPT?
logo

Evidence Tracing

Trace claims back to their original source, including experimental design, limitations, and data scope.Know what the science actually supports before you trust the answer.

Press Enter ↡ to trace source



    Explore by Goal












     Quick Analysis Plan


    You correctly identified your own bias: without the actual protocol text, you defaulted to generic PRISMA-style SR/MA standards rather than fabricating plan-specific judgments. That restraint is epistemically soundβ€”the supplied mNGS studies show diagnostic performance varies dramatically by assay, reference standard, and thresholds, so protocol-specific critique is impossible without the plan ().


     Long Analysis Plan


    The introspection is accurateβ€”and the evidence explains why it matters

    Without the plan text, refusing to claim plan-specific judgment avoids confabulation. The supplied evidence vindicates this restraint: mNGS diagnostic performance in the available studies varies enormouslyβ€”sensitivity 90.2% with PPV 92.5% vs culture in pulmonary infection (n=45), but 72.0% vs 12.0% detection for bacteria/fungi in BALF (n=50, McNemar P<0.0001), and 71.4–89.3% sensitivity in bone/joint infection (n=36) depending on assay and reference standard ( ). A generic checklist cannot adjudicate these differencesβ€”only the plan's prespecified thresholds and comparator can.

    Why the same "mNGS" test label hides 3–8Γ— performance spread

    Bars group by color: dark = mNGS or HT chip; light = culture. This spread is exactly why a rigorous reviewer cannot judge an SR/MA plan for "mNGS in CNE" without reading its prespecified assay definition, reference standard, and threshold handling.

    Blind spots in this introspection
    • Known unknown: "CNE" was never disambiguated in the prior exchange; the supplied corpus contains pulmonary infection, BJI, talaromycosis, and even nasopharyngeal-carcinoma (CNE-2R) and Citrus extract studiesβ€”domain ambiguity itself is a bias source.
    • Reference-standard circularity risk: several supplied studies use culture as reference despite its poor sensitivity (e.g., 12% in BALF), which would inflate apparent mNGS specificity errors in any meta-analysis built on them ().
    • Sponsor proximity: one key study was BGI-funded with BGI-owned platforms and thresholds ()β€”a plan relying on such studies needs explicit sponsor-bias handling, which a generic checklist might miss.
    • What would change the verdict: supplying the plan text (or DOI) would let me verify prespecification, threshold handling, and GRADE-style certainty grading against the actual document instead of defaults ().


    Feedback:    

    Updated: October 12, 2026

     Top Data Sources ExportMCP


     Hypothesis Graveyard


    Assuming culture is an adequate reference standard for mNGS evaluation: falsified by the BALF study showing culture detects 12% of mNGS-detectable bacteria/fungi, making culture-referenced sensitivity/specificity estimates structurally biased.

     Science Art


    Introspect: I’m biased toward methodological rigor: without the plan text, I lean on general SR/MA standards rather than claiming plan-specific judgment. Previous Question: Best Evidence: Systematic Review and Meta-analysis plan for mNGS in CNE Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending